Restless Legs Syndrome - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Restless Legs Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Restless Legs Syndrome - Pipeline Review, H2 2014', provides an overview of the Restless Legs Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Restless Legs Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Restless Legs Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Restless Legs Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Restless Legs Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Restless Legs Syndrome - Overview 7
Pipeline Products for Restless Legs Syndrome - Comparative Analysis 8
Restless Legs Syndrome - Therapeutics under Development by Companies 9
Restless Legs Syndrome - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Restless Legs Syndrome - Products under Development by Companies 12
Restless Legs Syndrome - Companies Involved in Therapeutics Development 13
Alexza Pharmaceuticals, Inc. 13
Ascendis Pharma A/S 14
Hisamitsu Pharmaceutical Co., Inc. 15
Ligand Pharmaceuticals, Inc. 16
Omeros Corporation 17
Serina Therapeutics, Inc. 18
Restless Legs Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 27
ACP-006 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
aplindore fumarate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AZ-008 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
OMS-527 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ropinirole hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SER-214 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Restless Legs Syndrome - Recent Pipeline Updates 34
Restless Legs Syndrome - Dormant Projects 36
Restless Legs Syndrome - Discontinued Products 37
Restless Legs Syndrome - Product Development Milestones 38
Featured News & Press Releases 38
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for Restless Legs Syndrome, H2 2014 7
Number of Products under Development for Restless Legs Syndrome - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H2 2014 13
Restless Legs Syndrome - Pipeline by Ascendis Pharma A/S, H2 2014 14
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 15
Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 16
Restless Legs Syndrome - Pipeline by Omeros Corporation, H2 2014 17
Restless Legs Syndrome - Pipeline by Serina Therapeutics, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 26
Restless Legs Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 34
Restless Legs Syndrome - Dormant Projects, H2 2014 36
Restless Legs Syndrome - Discontinued Products, H2 2014 37